10 biomarker development experts

Biomarker development experts in this group hold titles from assay platform director up to a Vice President at Sangamo Therapeutics and an AVP at Amgen, working in biomarker and bioanalytical platforms, clinical and translational biomarkers, companion diagnostics, and biomarkers and imaging. They suit a clinical team deciding which biomarkers to validate for patient selection or dose decisions, whether to move assays to a CRO, or when to start a companion diagnostic.

10 professionals10 companiesData retrieved October 4, 2026

Professionals to explore

  1. Alvydas Mikulskis

    LinkedIn

    Experience: Former Director Bioanalytical and Biomarker Development · Takeda

    $606 per 30-minute call

    From early to late stage clinical development, Alvydas Mikulskis describes hands-on development, transfer to CROs, validation and support of bioanalytical and biomarker assays. Mikulskis has been Senior Director Biomarkers & Imaging at Vertex Pharmaceuticals since 2021, after Director, Clinical Biomarkers & Imaging there (2019–2021), and was Director Bioanalytical and Biomarker Development at Takeda (2018–2019) and Principal Scientist, Bioassay at Biogen (2010–2014).

    Is this you? Claim your profile and get paid for calls.

  2. Gianluca Quintini

    LinkedIn

    Experience: Senior Director of Biomarker Development and Translational Science · CureVac

    $673 per 30-minute call

    Gianluca Quintini, based in Germany, has been Senior Director of Biomarker Development and Translational Science at CureVac since 2018 and describes experience across small molecules, biologics and RNA therapeutics, including assay development and HTS. Quintini was Associate Director Applied Clinical Biology at Dr. Reddy's Laboratories (2014–2018), Principal Scientist Biomarkers at Takeda (2012–2014) and Biomarker Specialist at Nycomed GmbH (2010–2012).

    Is this you? Claim your profile and get paid for calls.

  3. Lindsay King

    LinkedIn

    Experience: Executive Director, Head of Clinical and Translational Biomarkers · Pfizer

    $1,010 per 30-minute call

    At Pfizer, Lindsay King has been Executive Director, Head of Clinical and Translational Biomarkers since 2025. Earlier Pfizer titles include Senior Director, Biomarker Head, Clinical Bioanalytics, Translational Clinical Sciences (2023–2025), Senior Director, Clinical Biomarker and Translational Medicine Team Lead (2022–2023), Senior Director, Biomarker Clinical Assay Team Lead (2021–2022) and Director, Biomarker Clinical Assay Team Lead (2020–2021).

    Is this you? Claim your profile and get paid for calls.

  4. Mary Birchler

    LinkedIn

    Experience: Director, Biomarker and Bioanalytical Platforms · GSK

    $606 per 30-minute call

    Validated ligand-binding biomarker assays for clinical programs come from the group Mary Birchler leads as Director, Biomarker and Bioanalytical Platforms at GSK since 2024. GSK titles also include Associate Director (2019–2024), Investigator Group Leader, Exploratory Biomarkers (2017–2019) and Investigator Group Leader, Clinical Immunology (2012–2017), a fit for questions on validating ligand-binding assays for trials.

    Is this you? Claim your profile and get paid for calls.

  5. Meghna Das Thakur

    LinkedIn

    Experience: Senior Director, Biomarker Sciences and Diagnostics · Gilead Sciences

    $673 per 30-minute call

    Meghna Das Thakur was Director, Oncology Biomarker Sciences at Gilead Sciences (2022–2024) and has been Senior Director, Biomarker Sciences and Diagnostics there since 2024. Describing the design and execution of clinical biomarker strategies to uncover a molecule's mechanisms and validate predictive biomarkers, Das Thakur was Senior Principal Scientist at Genentech (2014–2022), a fit for predictive biomarker questions.

    Is this you? Claim your profile and get paid for calls.

  6. Mirella E Lazarov

    LinkedIn

    Experience: AVP, Head of Clinical Biomarkers and Diagnostics · Amgen

    $808 per 30-minute call

    As AVP, Head of Clinical Biomarkers and Diagnostics at Amgen since 2020, Mirella E Lazarov was earlier Head, Companion Diagnostics Center of Excellence at AbbVie (2016–2020) and Senior Director Biology, Head of Biomarkers at Gilead Sciences (2011–2014). Lazarov describes 20+ years across oncology, immunology and inflammation, ophthalmology, respiratory, renal disease and fibrosis, suiting companion diagnostic questions.

    Is this you? Claim your profile and get paid for calls.

  7. Ramakrishna Boyanapalli

    LinkedIn

    Experience: Senior Director, Biomarker Development · Bristol Myers Squibb

    $673 per 30-minute call

    Senior Director, Biomarker Development at Bristol Myers Squibb since 2022, Ramakrishna Boyanapalli describes the role as Translational & Biomarker Development, Neurology TRC, with a focus on biomarker strategy and assay development and validation. At Wave Life Sciences the titles were Senior Director (2021–2022), Director (2019–2021) and Associate Director (2017–2019), with Project Lead Sr. Scientist at Shire (2014–2017), suiting neurology biomarker strategy questions.

    Is this you? Claim your profile and get paid for calls.

  8. Tripti Gaur

    LinkedIn

    Experience: Biomarkers and Companion Diagnostics Lead · AVEO Oncology

    $404 per 30-minute call

    Patient selection and companion diagnostic strategies are part of Tripti Gaur's work as Biomarkers and Companion Diagnostics Lead at AVEO Oncology since 2025, along with developing biomarker development plans. Gaur was Executive Director and Head of Translational Medicine at AffyImmune Therapeutics (2024–2025), Senior Director and Head, Preclinical & Translational Sciences at Mustang Bio (2020–2024) and Associate Director and Biomarker Lead, Clinical Biomarkers and Exploratory Research at CRISPR Therapeutics (2019–2020).

    Is this you? Claim your profile and get paid for calls.

  9. Vaishali Shinde

    LinkedIn

    Experience: Senior Director, Translational & Clinical Assay Lead · Corbus Pharmaceuticals

    $539 per 30-minute call

    Vaishali Shinde has been Senior Director, Translational & Clinical Assay Lead at Corbus Pharmaceuticals since 2023 and was Director in that role (2022–2023). At Takeda, Shinde was Associate Director & Head of Molecular Pathology Group and Associate Director, CBID Project Lead -TAK-981 IO & multiple GI Projects (both 2020–2022), and describes experience in oncology, immuno-oncology, CAR-T and GI, suiting clinical assay questions.

    Is this you? Claim your profile and get paid for calls.

  10. Yanmei Lu

    LinkedIn

    Experience: Vice President, Biomarker and BioAnalytical Sciences · Sangamo Therapeutics, Inc.

    $943 per 30-minute call

    Gene therapies, cell therapies and biologics, from discovery through clinical development and regulatory submission, are what Yanmei Lu describes advancing over 20+ years. Lu has been Vice President, Biomarker and BioAnalytical Sciences at Sangamo Therapeutics, Inc. since 2021 and was Sr. Director in the same group (2018–2020), after Scientist at Genentech (2003–2018), a fit for biomarker strategy questions in gene and cell therapy programs.

    Is this you? Claim your profile and get paid for calls.

Choose the right perspective

For assay validation and bioanalytical questions, Mary Birchler, Alvydas Mikulskis and Vaishali Shinde fit best; for companion diagnostics and patient selection, Mirella E Lazarov and Tripti Gaur. Lindsay King, Yanmei Lu and Ramakrishna Boyanapalli cover clinical and translational biomarker strategy, Meghna Das Thakur predictive oncology biomarkers, and Gianluca Quintini biomarker work across small molecules, biologics and RNA therapeutics.

Questions to take into the conversation

  1. 01What level of assay validation does a biomarker need before it can drive a dose or go/no-go decision in an early trial?
  2. 02When should a sponsor start companion diagnostic planning, and how does that change the biomarker plan for later trials?
  3. 03Which bioanalytical and biomarker assays are worth keeping in-house, and which should be transferred to a CRO?

About this directory

This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.

Other perspectives in Pharmaceuticals